[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351463-105":59,"doc-detail-351463-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","natural-killer-cell-therapy-in-ovarian-cancer-from-preclinical-potentials-to-clinical-applications-and-combination-strategies","Natural Killer Cell Therapy in Ovarian Cancer - From Preclinical Potentials to Clinical Applications and Combination Strategies","","Ovarian cancer represents a leading cause of mortality among gynecologic cancers, with limited therapeutic options for advanced and recurrent disease, highlighting an urgent need for innovative immunotherapies. Natural Killer (NK) cells, functioning as crucial effector cells of the innate immune system, have been identified as promising candidates for ovarian cancer treatment. This review systematically examines NK cell-based therapies from preclinical rationale to clinical translation, and evaluates combination strategies. It addresses challenges posed by the immunosuppressive tumor microenvironment and proposes approaches to enhance infiltration and activity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/natural-killer-cell-therapy-in-ovarian-cancer-from-preclinical-potentials-to-clinical-applications-and-combination-strategies/351463/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/natural-killer-cell-therapy-in-ovarian-cancer-from-preclinical-potentials-to-clinical-applications-and-combination-strategies/351463.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is NK cell therapy considered promising for ovarian cancer?","Question",{"text":112,"@type":113},"NK cells act as innate immune effector cells with anti-tumor capabilities and can recognize tumor cells without prior sensitization. They also contribute to tumor lysis and can initiate adaptive immunity via cytokines and chemokines.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major barriers reduce the clinical efficacy of NK cell therapies in ovarian cancer?",{"text":117,"@type":113},"The ovarian cancer tumor microenvironment is highly immunosuppressive, and barriers to NK cell infiltration lead to dysfunctional infiltrating NK cells, limiting therapeutic effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What strategies are discussed to enhance NK cell activity and therapy outcomes?",{"text":121,"@type":113},"The review discusses cytokine-based agents, NK cell engagers, and chimeric antigen receptor (CAR) NK cells, aiming to boost NK cell function and support combination immunotherapies with standard treatments.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351463,1790211485,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2026; 22(7): 3509-3521. doi: 10.7150/ijbs.130260  \nReview  \nNatural Killer Cell Therapy in Ovarian Cancer: From Preclinical Potentials to Clinical Applications and Combination Strategies  \nTian Chen1, Jiaqi Lu1,2􀀍, Haiou Liu1􀀍  \n1. Obstetrics & Gynecology Hospital of Fudan University, Shanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai, China.  \n2. Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.  \n􀀍 Corresponding authors: Hai-ou Liu, PhD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, No. 128, Shen-yang Road, Yangpu District, Shanghai 200011, China; Tel: +86-021-33189900; E-mail: [liuhaiou@fudan.edu.cn. Jia-qi](liuhaiou@fudan.edu.cn. Jia-qi)[ ](liuhaiou@fudan.edu.cn. Jia-qi)[Lu](Lu), [MD](MD), [PhD](PhD), [Department of Gynecology](Department of Gynecology), [Obstetrics and Gynecology Hospital](Obstetrics and Gynecology Hospital), [Fudan University](Fudan University), [No. 128](No. 128), [Shen](Shen)-yang Road, Yangpu District, Shanghai 200011, China; Tel: +86-021-33189900 ext. 2020; Email: [lujiaqidoc@163.com](lujiaqidoc@163.com).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.12.19; Accepted: 2026.03.04; Published: 2026.03.17  \nAbstract  \nOvarian cancer represents a leading cause of mortality among gynecologic cancers, with limited therapeutic options for advanced and recurrent disease, highlighting an urgent need for innovative immunotherapies. Natural Killer (NK) cells, functioning as crucial effector cells of the innate immune system, have been identified as promising candidates for ovarian cancer treatment. This review systematically examines the evolving landscape of NK cell-based therapies for ovarian cancer, spanning their preclinical rationale, clinical translation, and innovative combination strategies. Nevertheless, the highly immunosuppressive tumor microenvironment (TME) of ovarian cancer and barriers to tumor infiltration pose significant challenges to their clinical efficacy. Here, we discuss various therapeutic strategies (such as cytokine-based agents, NK cell engagers and chimeric antigen receptor NK cells) designed to enhance NK cell activity, which leverage the unique characteristics of NK cells to complement standard treatments and potentiate combination immunotherapies. Ongoing preclinical and clinical investigations are paramount to converting these advances into efficacious therapies, ultimately revolutionizing the therapeutic paradigm for ovarian cancer.  \nKeywords: ovarian cancer, natural killer cells, immunotherapy, tumor microenvironment, clinical trials, chimeric antigen receptor  \n1. Introduction  \nOvarian cancer, as one of the common malignant tumors of the female reproductive system, presents a significant global clinical challenge due to its high mortality and recurrence rates [1, 2] . Currently, first-line treatment for ovarian cancer is based on cytoreductive surgery combined with platinumtaxane chemotherapy. However, as most patients are diagnosed at an advanced stage and frequently develop chemoresistance [3], the efficacy of these conventional therapies is significantly limited, resulting in an unfavorable prognosis. Therefore, innovative therapeutic strategies are urgently required to improve the outcomes in ovarian cancer  \npatients. In recent years, immunotherapy has made breakthrough progress in ovarian cancer treatment, and with ongoing characterization of its intricate tumor microenvironment [4, 5], it has become clear th","cbCaigrAX0EHe2JT","https://ap.wps.com/l/cbCaigrAX0EHe2JT","pdf",2277421,13,"English","# Introduction\n# The antitumor functions of NK cells","[{\"question\":\"Why is NK cell therapy considered promising for ovarian cancer?\",\"answer\":\"NK cells act as innate immune effector cells with anti-tumor capabilities and can recognize tumor cells without prior sensitization. They also contribute to tumor lysis and can initiate adaptive immunity via cytokines and chemokines.\"},{\"question\":\"What major barriers reduce the clinical efficacy of NK cell therapies in ovarian cancer?\",\"answer\":\"The ovarian cancer tumor microenvironment is highly immunosuppressive, and barriers to NK cell infiltration lead to dysfunctional infiltrating NK cells, limiting therapeutic effectiveness.\"},{\"question\":\"What strategies are discussed to enhance NK cell activity and therapy outcomes?\",\"answer\":\"The review discusses cytokine-based agents, NK cell engagers, and chimeric antigen receptor (CAR) NK cells, aiming to boost NK cell function and support combination immunotherapies with standard treatments.\"}]","Natural Killer Cell Therapy in Ovarian Cancer - From Preclinical Potentials to Clinical Applications and Combination Strategies | PDF",1790094292,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cb002e0fe77d41a975dc8c9d1ed59de.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11c6be4419aa89097af826053640f3e0.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2bc63153300bb849234a5e4a5172d27.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca915186637064c7015b649ff0f3113d.webp",980,1268]